

SANOFI INDIA (SANOFI-IN)

Pharma. & Medical Research / Pharmaceuticals / Pharmaceuticals

DETAILED STOCK REPORT

Report Date: 2024-May-05

Last Close 8,624.25 (INR)	Avg Daily Vol 19,485	52-Week High 9,380.00	Trailing PE 36.0	Annual Div 147.00	ROE 52.6%	LTG Forecast --	1-Mo Return -0.22%
2024 May 03 NSE Exchange	Market Cap 198.6B	52-Week Low 5,425.00	Forward PE 30.4	Dividend Yield 1.7%	Annual Rev 28.5B	Inst Own 25.7%	3-Mo Return -3.3%

AVERAGE SCORE


NEUTRAL OUTLOOK: SANOFI's current score is relatively in-line with the market.

AVERAGE SCORE
6

Score Averages

Pharmaceuticals Group: 4.8	Mid Market Cap: 6.7
Pharma. & Medical Research Sector: 4.7	BSE Sensex Index: 8.1

Average Score Trend (4-Week Moving Avg)



Peers	-6M	-3M	-1M	-1W	Current	1Y Trend
CAPLIPOINT	7	9	9	8	9	
AJANTPHARM	8	9	8	7	7	
GLENMARK	4	8	6	6	6	
SANOFI	5	7	5	6	6	
WOCKPHARMA	4	6	4	4	3	

HIGHLIGHTS


- The score for Sanofi India last changed from 5 to 6 on 2024-04-28.
- The recent change in the Average Score was primarily due to an improvement in the Earnings and Fundamental component scores.

I/B/E/S MEAN

Buy

3 Analysts



Mean recommendation from all analysts covering the company on a standardized 5-point scale.



PRICE AND VOLUME CHARTS

1-Year Return: 59.2%

5-Year Return: 56.4%




BUSINESS SUMMARY

Sanofi India Limited is an India-based company, which is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company produces pharmaceutical formulations, dosage forms and offer a range of medicines across various therapeutic areas. Its product portfolio is focused on five therapeutic areas: diabetes, epilepsy, cardiology, allergy and pain care. In the diabetes area, the Company has an insulin portfolio under the brand name of Lantus, which helps in controlling high blood sugar in adults and children with diabetes mellitus. It also provides Toustar pen, along with dedicated Toujeo cartridges, addressing the need for a reusable delivery device. Combiflam, its product, helps to reduce pain and inflammation in conditions like headache, muscle and joint pain, and also reduces fever. Its brands also include Cardace, Allegra, Avil and Frisium. The Company has its own manufacturing facility in Goa. It has around 12 contract manufacturing organizations.

INDICATOR COMPONENTS

AVERAGE SCORE
6

The **AVERAGE SCORE** combines the quantitative analysis of five widely-used investment decision making tools: Earnings, Fundamental, Relative Valuation, Risk, and Price Momentum. A simple average of the underlying component ratings is normally distributed to rank stocks on a 1-10 scale (10 being awarded to the most favorable). These factors may be evaluated differently using alternative methodologies and the importance of individual factors varies across industries, market capitalization and investment styles. Additional criteria should always be used to evaluate a stock.



PEER ANALYSIS

Currency in INR

Average Score	Ticker	PRICE MOMENTUM				VALUATION		FUNDAMENTAL		ANALYSTS		# of Analysts
		Price (2024-05-03)	1-Mo Return	3-Mo Return	1-Yr Return	Market Cap	Trailing PE	Forward PE	Dividend Yield	Net Margin	LTG Forecast	
8	SUNPHARMA	1,511.15	-6.7%	6.7%	56.8%	3.6T	40.7	37.5	0.83%	18.5%	-- Buy	31
9	CIPLA	1,424.75	-3.2%	2.3%	54.8%	1.2T	31.0	27.3	0.60%	12.3%	-- Buy	32
9	ZYDUSLIFE	997.40	0.98%	31.0%	91.5%	1.0T	33.8	28.3	0.60%	15.9%	-- Hold	27
7	AJANTPHARM	2,383.85	5.7%	9.9%	85.7%	300.2B	36.8	32.3	1.6%	19.4%	-0.40% Buy	10
6	GLENMARK	1,053.30	6.0%	18.9%	94.6%	297.2B	174.3	39.0	0.24%	-6.1%	-- Hold	10
6	SANOFI	8,624.25	-0.22%	-3.3%	59.2%	198.6B	36.0	30.4	1.7%	21.1%	-- Buy	3
9	CAPLIPOINT	1,298.75	-1.3%	-7.3%	89.6%	98.6B	22.7	21.7	0.35%	26.8%	-- Strong Buy	2
3	WOCKPHARMA	555.15	-5.5%	25.2%	231%	85.2B	--	--	--	-18.0%	-- --	--
5	STAR	886.55	5.9%	26.7%	161.7%	81.5B	--	73.9	0.17%	-2.5%	-- Buy	2
7	PGHL	4,750.60	-0.27%	-8.4%	1.1%	78.9B	34.4	--	2.1%	18.3%	-- --	--
6	GUJTHEM	404.90	7.8%	19.6%	176.7%	29.4B	53.5	--	0.23%	35.2%	-- --	--
6.8	Average	2,171.88	0.85%	11.0%	100.2%	631.8B	51.5	36.3	0.84%	12.8%	-0.40% Buy	14.6

PEER COMPANIES

AJANTPHARM	Ajanta Pharma	PGHL	Procter & Gamble Health
CAPLIPOINT	Caplin Point Laboratories	STAR	Strides Pharma Science
CIPLA	Cipla	SUNPHARMA	Sun Pharmaceutical Industries
GLENMARK	Glenmark Pharmaceuticals	WOCKPHARMA	Wockhardt
GUJTHEM	Gujarat Themis Biosyn	ZYDUSLIFE	Zybus Lifesciences

SANOFI INDIA (SANOFI-IN)

Pharma. & Medical Research / Pharmaceuticals / Pharmaceuticals

DETAILED STOCK REPORT

Report Date: 2024-May-05


EARNINGS Currency in INR

NEUTRAL OUTLOOK: Mixed earnings expectations and performance.

EARNINGS 5

Earnings Score Averages

Pharmaceuticals Group:	5.8	Mid Market Cap:	5.4
Pharma. & Medical Research Sector:	5.5	BSE Sensex Index:	6.7




Peers	-6M	-3M	-1M	-1W	Current	1Y Trend
GLENMARK	3	10	10	10	10	
CAPLIPOINT	7	7	7	7	7	
SANOFI	3	3	2	2	5	
AJANTPHARM	8	5	5	5	4	
WOCKPHARMA	NR	NR	NR	NR	NR	

EARNINGS INDICATORS

Earnings Surprises (33.3% weight)

Estimate Revisions (33.3% weight)

Recommendation Changes (33.3% weight)



Last 4 Quarters

# Positive Surprises (>2%)	0
# Negative Surprises (<-2%)	1
# In-Line Surprises (within 2%)	0
Avg Surprise	-16.7%

Last 4 Weeks

# Up Revisions	0
# Down Revisions	1
Avg Up Revisions	0.00%
Avg Down Revisions	-33.3%

Last 120 Days


# Broker Upgrades	1
# Broker Downgrades	0

HIGHLIGHTS

- Sanofi India currently has a relatively neutral Earnings Rating of 5. The average Earnings Rating for its Pharmaceuticals industry is 5.8 and the S&P BSE SENSEX index average is 6.7.
- Over the past 90 days, the consensus price target for SANOFI has increased notably from 7,640.00 to 9,210.00, a gain of 20.5%.

PRICE TARGET

The chart indicates where analysts predict the stock price will be within the next 12 months, as compared to the current price.



12-Month Price Target

Mean (INR)	9,210.00
High	11,300.00
Low	7,250.00
Target vs. Current	6.8%
# of Analysts	5



SANOFI INDIA (SANOFI-IN)

Pharma. & Medical Research / Pharmaceuticals / Pharmaceuticals


DETAILED STOCK REPORT

Report Date: 2024-May-05


EARNINGS PER SHARE

Earnings per share (EPS) is calculated by dividing a company's earnings by the number of shares outstanding. Analysts tend to interpret a pattern of increasing earnings as a sign of strength and flat or falling earnings as a sign of weakness.

The charts provide a comparison between a company's actual and estimated EPS, including the high and low forecasts.



Quarterly		
Mean	--	--
High	--	--
Low	--	--
# of Analysts	--	--



Annual	2024	2025
Mean	283.9	316.8
High	289.9	322.5
Low	277.3	311.5
# of Analysts	3	3

MEAN ESTIMATE TREND | **ANALYST RECOMMENDATIONS**

	Q	Q	Y	Y	Price Target
	--	--	2024	2025	
Current	--	--	283.9	316.8	9,210.00
30 Days Ago	--	--	284.1	317.2	9,210.00
90 Days Ago	--	--	287.2	318.6	7,640.00
% Change (90 Days)	--	--	-1.1%	-0.60%	20.5%

Current Fiscal Year End: 24-12
Next Expected Report Date: 2024-05-13

I/B/E/S Mean: **Buy (3 Analysts)**

Strong Buy	1
Buy	2
Hold	0
Sell	0
Strong Sell	0

EARNINGS SURPRISES

Comparing a company's actual earnings to the mean expectation of analysts results in a difference referred to as a 'positive' or 'negative' surprise. Research has shown that when a company reports a surprise, it is often followed by more of the same surprise type.

Surprise Summary (Last 12 Quarters)


Surprise Type	Amount	Percent
Positive Quarters (> 2%)	0	--
Negative Quarters (< -2%)	4	100.0%
In-Line Quarters (within 2%)	0	--

Surprise Detail (Last 6 Periods)

Surprise Type	Announce Date	Period End Date	Actual EPS	Mean EPS	Surprise (%)
Negative	2023-11-08	2023-09-30	65.950	79.200	-16.7%
Negative	2022-04-26	2022-03-31	52.230	77.400	-32.5%
Negative	2022-02-24	2021-12-31	39.250	63.400	-38.1%
Negative	2021-10-26	2021-09-30	17.630	141.0	-87.5%

ANNUAL REVENUE

A pattern of increasing sales in conjunction with a rising EPS may influence a buy recommendation, while flat or falling sales and faltering earnings may explain a sell recommendation. A rising EPS with flat or falling sales may result from increased cost efficiency and margins, rather than market expansion. This chart shows the sales forecast trend of all analysts and the highest and lowest projections for the current and next fiscal year.



	2024	2025
Mean	30.3B	33.3B
High	31.1B	34.5B
Low	29.0B	31.8B
Forecasted Growth	6.2%	16.8%
# of Analysts	3	3

SANOFI INDIA (SANOFI-IN)

Pharma. & Medical Research / Pharmaceuticals / Pharmaceuticals

DETAILED STOCK REPORT

Report Date: 2024-May-05

FUNDAMENTAL


FUND-AMENTAL
6

NEUTRAL OUTLOOK: Fundamentals relatively in-line with the market.

Fundamental Score Averages

Pharmaceuticals Group: **5.1** Mid Market Cap: **6.4**
Pharma. & Medical Research Sector: **5.1** BSE Sensex Index: **7.1**

Fundamental Score Trend



Peers	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Current	3Y Trend
AJANTPHARM	7	7	7	NR	9	[Bar Chart]
CAPLIPOINT	8	8	8	NR	8	[Bar Chart]
SANOFI	8	8	2	NR	6	[Bar Chart]
WOCKPHARMA	2	2	1	NR	2	[Bar Chart]
GLENMARK	6	6	3	NR	1	[Bar Chart]


FUNDAMENTAL INDICATORS

Profitability
(25% weight)

Debt
(25% weight)

Earnings Quality
(25% weight)

Dividend
(25% weight)



Revenue Growth	2.9%	Current Ratio	1.9	Oper. Cash Yield	-54.2%	Dividend Growth	-13.9%
For year over year ending 2023-12		For interim period ending 2023-12		For latest 12 months ending --		For year over year ending 2023-12	
Gross Margin	55.6%	Debt-to-Capital	1.4%	Accruals	74.0%	Dividend Payout	63.8%
For latest 12 months ending 2023-12		For annual period ending 2023-12		For latest 12 months ending 2023-12		For latest 12 months ending 2023-12	
Return On Equity	52.6%	Interest Funding	0.3%	Days Sales In Inv.	160.7	Dividend Coverage	0.7
For interim period ending 2023-12		For interim period ending 2023-12		For annual period ending 2023-12		For annual period ending 2023-12	
Net Margin	21.1%	Interest Coverage	473.0	Days Sales In Rec.	21.4	Current Div. Yield	1.7%
For latest 12 months ending 2023-12		For interim period ending 2023-12		For annual period ending 2023-12		For latest 12 months ending 2024-05	

HIGHLIGHTS

- The Fundamental Rating for Sanofi India declined significantly over the last quarter from a bullish 8 to a relatively neutral 6. The average Fundamental Rating for its Pharmaceuticals industry group is 5.1 and the S&P BSE SENSEX index average is 7.1.
- The company's gross margin has been higher than its industry group average for each of the past five years.
- The company's current ratio has been higher than its industry group average for each of the past five years.
- The days sales in receivables for SANOFI is the lowest within its Pharmaceuticals industry group.
- Of the 198 firms within the Pharmaceuticals industry group, Sanofi India is among 80 companies that pay a dividend. The stock's dividend yield is currently 1.7%.



SANOFI INDIA (SANOFI-IN)

Pharma. & Medical Research / Pharmaceuticals / Pharmaceuticals

DETAILED STOCK REPORT

Report Date: 2024-May-05


RELATIVE VALUATION

NEUTRAL OUTLOOK: Multiples relatively in-line with the market.

RELATIVE VALUATION
5


Relative Valuation Score Averages

Pharmaceuticals Group:	5.2	Mid Market Cap:	4.9
Pharma. & Medical Research Sector:	5.2	BSE Sensex Index:	6.0



Peers	-6M	-3M	-1M	-1W	Current	1Y Trend
CAPLIPOINT	5	5	6	6	6	
SANOFI	4	4	5	5	5	
AJANTPHARM	4	4	4	4	4	
WOCKPHARMA	8	5	3	3	4	
GLENMARK	4	4	3	3	3	

RELATIVE VALUATION INDICATORS



Indicator	Value	5-Yr Average	Rel. to 5-Yr Avg.
Price to Sales	6.8	5.7	21% Premium
Trailing PE	36.0	30.6	18% Premium
Forward PE	30.4	30.4	0.1% Discount
BSE Sensex Index	3.5	22.8	97% Premium
BSE Sensex Index	24.9	22.8	45% Premium
BSE Sensex Index	22.8	22.8	33% Premium

HIGHLIGHTS

- Sanofi India currently has a Relative Valuation Rating of 5 while the S&P BSE SENSEX index has an average rating of 6.0.
- SANOFI is currently valued at a premium to the S&P BSE SENSEX index based on both Price to Sales ratio and Trailing P/E.
- SANOFI's Price to Sales ratio of 6.8 represents a 21% Premium to its 5-year average of 5.7.
- SANOFI's Trailing P/E of 36.0 represents a 18% Premium to its 5-year average of 30.6.
- SANOFI's Forward P/E of 30.4 represents a 0.1% Discount to its 5-year average of 30.4.

SANOFI INDIA (SANOFI-IN)

Pharma. & Medical Research / Pharmaceuticals / Pharmaceuticals


DETAILED STOCK REPORT

Report Date: 2024-May-05

PRICE TO SALES

The most recent week's close price divided by the revenue per share.

Price to Sales: 6.8
5-Year Average: 5.7
BSE Sensex Index Average: 3.5
Pharmaceuticals Group Average: 5.2



TRAILING PE

The most recent week's close price divided by the sum of the four most recently reported quarterly earnings.

Trailing PE: 36.0
5-Year Average: 30.6
BSE Sensex Index Average: 24.9
Pharmaceuticals Group Average: 41.6



FORWARD PE

The most recent week's close price divided by the sum of the four upcoming quarterly consensus estimates.


Forward PE: 30.4
5-Year Average: 30.4
BSE Sensex Index Average: 22.8
Pharmaceuticals Group Average: 36.9



FORWARD PEG

The Forward P/E divided by the five-year forecasted growth rate.

Forward PEG: --
5-Year Average: --
BSE Sensex Index Average: 1.5
Pharmaceuticals Group Average: 1.7



SANOFI INDIA (SANOFI-IN)

Pharma. & Medical Research / Pharmaceuticals / Pharmaceuticals

DETAILED STOCK REPORT

Report Date: 2024-May-05


RISK

POSITIVE OUTLOOK: Consistent return patterns (low volatility).

RISK
10


Risk Score Averages

Pharmaceuticals Group:	6.3	Mid Market Cap:	7.7
Pharma. & Medical Research Sector:	6.3	BSE Sensex Index:	9.4



Peers	-6M	-3M	-1M	-1W	Current	1Y Trend
CAPLIPOINT	9	9	9	9	10	
SANOFI	10	10	10	10	10	
AJANTPHARM	9	10	10	9	9	
GLENMARK	9	9	9	9	9	
WOCKPHARMA	9	6	7	8	7	

RISK INDICATORS



Daily Returns (Last 90 Days)	Standard Deviation	Beta vs. BSE Sensex	0.26	Correlation vs. BSE Sensex
Best: 4.2%	Last 90 Days: 1.67	Positive Days Only: -0.17		Last 90 Days: 25%
Worst: -3.7%	Last 60 Months: 6.87	Negative Days Only: 0.81		Last 60 Months: 36%
Monthly Returns (Last 60 Months)	Intra-Day Swing (Last 90 Days)	Beta vs. Group	0.46	Correlation vs. Group
Best: 24.4%	Average: 2.6%	Positive Days Only: 0.23		Last 90 Days: 31%
Worst: -14.3%	Largest: 5.0%	Negative Days Only: 0.32		Last 60 Months: 33%

HIGHLIGHTS

- Sanofi India currently has a Risk Rating of 10 while the S&P BSE SENSEX index has an average rating of 9.4.
- On days when the market is up, SANOFI shares typically decrease. Furthermore, on days when the market is down, the shares tend to decline less than the S&P BSE SENSEX index.
- In both short-term and long-term periods, SANOFI has shown average correlation (> 0.2 and < 0.4) with the S&P BSE SENSEX index. Thus, this stock would provide only average levels of diversification to a portfolio similar to the broader market.
- Over the last 90 days, SANOFI shares have been more volatile than the overall market, as the stock's daily price fluctuations have exceeded that of 75% of S&P BSE SENSEX index firms.

RISK ANALYSIS

Peers	Last 90 Days			Last 60 Months		
	Best Daily Return	Worst Daily Return	# Days Up / # Days Down	Largest Intra-Day Swing	Best Monthly Return	Worst Monthly Return
SANOFI	4.2%	-3.7%	29 / 31	5.0%	24.4%	-14.3%
AJANTPHARM	6.7%	-3.8%	35 / 25	10.4%	19.1%	-21.8%
CAPLIPOINT	4.3%	-4.3%	29 / 31	9.2%	38.3%	-18.9%
GLENMARK	7.7%	-4.9%	34 / 25	9.8%	63.7%	-25.8%
WOCKPHARMA	13.2%	-5.3%	26 / 33	12.3%	54.1%	-43.8%
BSE Sensex	1.7%	-1.2%	36 / 23	2.1%	14.4%	-23.1%



SANOFI INDIA (SANOFI-IN)

Pharma. & Medical Research / Pharmaceuticals / Pharmaceuticals

DETAILED STOCK REPORT

Report Date: 2024-May-05

PRICE MOMENTUM


PRICE
MOMENTUM
4

Currency in INR


NEUTRAL OUTLOOK: Performance relatively in-line with the market.

Price Momentum Score Averages

Pharmaceuticals Group: 3.4	Mid Market Cap: 6.2
Pharma. & Medical Research Sector: 3.3	BSE Sensex Index: 5.5



PRICE MOMENTUM INDICATORS



Relative Strength Indicator (Scale from 1 to 100)

	SANOFI	Industry Avg
Last 10 Days	66	54
Last 50 Days	54	53
Last 200 Days	55	53


Average Monthly Return (Last 10 Years)

	May	Jun	Jul
Company Avg	3.4%	0.81%	5.6%
Industry Avg	-0.63%	3.7%	6.3%
Industry Rank	87 of 99	70 of 98	21 of 99

PRICE PERFORMANCE

Daily close prices are used to calculate the performance of the stock as compared to a relevant index over five time periods.

■ SANOFI
■ BSE Sensex



	SANOFI	BSE Sensex
Close Price (2024-05-03)	8,624.25	73,880
52-Week High	9,380.00	75,038
52-Week Low	5,425.00	61,054

- On 2024-05-03, SANOFI closed at 8,624.25, 8.1% below its 52-week high and 59.0% above its 52-week low.
- SANOFI shares are currently trading 3.8% above their 50-day moving average of 8,306.15, and 8.8% above their 200-day moving average of 7,929.58.
- The S&P BSE SENSEX index is currently 1.5% below its 52-week high and 21.0% above its 52-week low.



DETAILED STOCK REPORT TIPS

The Stock Report from LSEG is a comprehensive, company-specific analysis that includes a proprietary Stock Rating along with underlying component indicators and supportive data elements. The report is updated daily, although some of the data elements and the ratings are updated weekly.

Average Score

The Stock Reports Plus Average Score combines a quantitative analysis of five widely-used investment decision making tools - Earnings, Fundamental, Relative Valuation, Risk, and Price Momentum. First, a simple average of the five underlying component ratings is calculated. Then, a normal distribution is used to rank each stock across the market on a scale of 1 to 10, with 10 being most favorable. A score of 8 to 10 is considered positive, 4 to 7 is neutral, and 1 to 3 is negative. These five factors may be evaluated differently using alternative methodologies, and the importance of individual factors varies across industry groups, market capitalization and investment styles. Additional criteria should always be used to evaluate a stock.

A company must have sufficient data available for at least three of the five component indicators in order to receive an overall Average Score. Approximately 85% of the stocks within the coverage universe meet the criteria to generate a score.

Indicator Components

The five indicators that comprise the stock rating are displayed. Like the stock rating, the component rating scale is 1 to 10, with 10 being best. A company will receive an 'NR' for No Rating if the required data elements or criteria are not met. A detailed section for each component is included in the report.

Indicator Trends

Within each component section, historical score trends are displayed, typically using a 4-week moving average over a timeframe of the past three years. The dotted orange line indicates the average of the scores over those three years. The most recent occurrences of the best and worst scores are also displayed on the chart in grey boxes to put the current score into historical context.

Next to the trend chart for the company, current score averages are included, along with peer company comparisons of values from 6 months ago, 3 months ago, 1 month ago, the most recent value from 1 week ago, and the current score. The four closest industry peers are presented based on similar market capitalization.

Peer Analysis

- The Refinitiv Business Classification (TRBC) schema is used for industry comparisons. It is designed to track and display the primary business of a corporation by grouping together correlated companies that offer products and services into similar end markets. The system includes 10 Economic Sectors, 28 Business Sectors, 54 Industry Groups, and 136 Industries.
- The Peer Analysis section of the report compares the company to its ten closest peers. The peers are selected from the industry based on similar market capitalization. The peer listing may have fewer than ten companies if there are fewer than ten companies classified within that industry.

Highlights

The automated text-generation system from LSEG creates highlights summarizing the most noteworthy data. The bullets will vary by company and will change from week to week as different criteria are met.

Earnings

The Earnings Rating is based on a combination of three factors: earnings surprises, estimate revisions, and recommendation changes. Each factor is equally weighted. Then, equal deciles are used to rank each stock across the market on a scale of 1 to 10, with 10 being most favorable. A stock needs to have at least two of the three earnings factors in order to receive a score.

- Earnings Surprises - The number of positive and negative surprises within the last 4 periods (quarters or years).
- Estimate Revisions - The number of up and down revisions and the average percentage change of those revisions within a 4 week period.
- Recommendation Changes - The number of broker upgrades and downgrades in the last 120 days.

Price Target

The price target is based on the predictions of analysts covering the stock and shows the high, low and mean price expected within the next 12 months.

Earnings Per Share

The quarterly and annual earnings per share are presented when available, along with the mean, high and low. Quarterly data is displayed for the past 4 quarters (actual) and the next 2 quarters (estimated). Annual data is displayed for the past 2 years (actual) and the next 2 years (estimated).

Mean Estimate Trend

The mean estimates show how the consensus has changed over the past 30 days and 90 days for the upcoming two quarters (when available) and two years. The percentage change is calculated for the company as a means for comparison by measuring the difference between the current consensus estimate and that of 90 days ago.

Analyst Recommendations

The I/B/E/S Mean is the average recommendation of all analysts covering the stock, as provided by I/B/E/S, the Institutional Brokers Estimate System, from LSEG. The recommendations are presented on a five-point standardized scale: strong buy, buy, hold, sell, and strong sell.

Earnings Surprises

- The surprise summary includes the total number of time periods (and percentage) in the last 12 quarters (quarterly) or last 4 years (annual) in which earnings surprises were positive, negative, or in-line. In order to be recognized as a positive or negative surprise, the percent must be greater than 2% above or 2% below the consensus, respectively.
- The surprise detail section includes a listing of the company's quarterly earnings reported for the most recent 6 periods (quarters or years). The consensus analyst estimate is provided to determine if the actual earnings report represented a positive surprise, negative surprise, or in-line result.

Fundamental

The Fundamental Rating is based on a combination of four fundamental component factors: profitability, debt, earnings quality, and dividend. Companies that do not pay a dividend are not penalized. Each factor is equally weighted. Then, equal deciles are used to rank each stock across the market on a scale of 1 to 10, with 10 being most favorable. A stock needs to have at least two of the four fundamental factors present in order to receive a score.

Profitability

- Revenue Growth: $(\text{Net Sales} - \text{Previous Net Sales}) / \text{Previous Net Sales}$
- Gross Margin: $\text{Gross Profit} / \text{Net Sales}$
- Return on Equity: $\text{Net Income} / \text{Total Equity}$
- Net Margin: $\text{Net Profit} / \text{Net Sales}$

Debt

- Current Ratio: $\text{Current Assets} / \text{Current Liabilities}$
- Debt-to-Capital: $\text{Total Debt} / \text{Total Capital}$
- Interest Funding: $(\text{Interest Expense on Debt} + \text{Preferred Cash Dividends}) / \text{Funds from Operations}$
- Interest Coverage: $\text{Earnings before Interest and Taxes} / (\text{Interest Expense on Debt} + \text{Preferred Cash Dividends})$

Earnings Quality

- Operating Cash Yield: $(\text{Operating Cash Flow} - \text{Net Income}) / \text{Net Income}$
- Accruals: $(\text{Net Income} - \text{Operating Cash Flow} - \text{Investing Cash Flow}) / \text{Average Net Operating Assets}$
- Days Sales in Inventory: $365 / (\text{Cost of Goods Sold} / \text{Inventory})$
- Days Sales in Receivables: $365 / (\text{Net Sales} / \text{Receivables})$

Dividend

The company must have a current dividend yield.

- Dividend Growth Rate: $(\text{Dividends per Share} - \text{Previous Dividends per Share}) / \text{Previous Dividends per Share}$
- Dividend Funding: $\text{Dividends} / \text{Operating Cash Flow}$
- Dividend Coverage: $(\text{Pre-Tax Income} + \text{Interest Expense}) / (\text{Interest Expense} + \text{Dividends})$
- Dividend Yield: $\text{Annual Dividends per Share} / \text{Current Market Price per Share}$

Indicator Trend

The fundamental indicator trend displays either quarterly scores over the past three years or annual scores over the past six years, depending on the reporting periods for the country. The best and worst scores can be easily determined from the values shown on the chart for each quarter or year.

Relative Valuation

The Relative Valuation Rating is based on a combination of three component factors: Price to Sales, Trailing P/E, and Forward P/E. Each factor is equally weighted. Equal deciles are then used to rank each stock across the market on a scale of 1 to 10, with 10 being most favorable. These common valuation metrics are evaluated against the overall market, the index, and the company's own historic 5-year averages. A stock needs to have at least one of the three relative valuation factors in order to receive a score.

- Price to Sales: $\text{Close Price} / (\text{Sales for 4 Quarters or 1 Year} / \text{Shares Outstanding})$

SANOFI INDIA (SANOFI-IN)

Pharma. & Medical Research / Pharmaceuticals / Pharmaceuticals

DETAILED STOCK REPORT

Report Date: 2024-May-05

- Trailing P/E: Close Price / Most Recent 4 Quarters or 1 Year of Earnings
- Forward P/E: Close Price / Upcoming 4 Quarters or 1 Year of Earnings

Valuation Averages

Negative values are excluded when calculating the averages. A maximum value of 100 is placed on Trailing P/E and Forward P/E, a maximum value of 5 is placed on Forward PEG, and a maximum value of 20 is placed on Price to Sales when calculating the averages. Higher values are rounded down to the maximum for the averages.

Valuation Multiples

The valuation multiples provide the Trailing P/E, Forward P/E, Forward PEG, and Price to Sales for the company and the relevant index average. In addition, a comparison of the current company's values to its 5-year average and an industry average are presented. A discount occurs when the company's ratio is valued more favorably (lower) than that to which it is compared.

Risk

The Risk Rating displays stocks on a scale of 1 to 10 with 10 being awarded to the least risky stocks. It is derived by looking at a series of long-term (5-year) and short-term (90-day) stock performance measures including volatility, magnitude of returns, beta, and correlation. Each factor is equally weighted. Then, equal deciles are used to rank each stock across the market. A stock needs to have at least two of the four risk factors in order to receive a score.

- Magnitude of Returns - The best / worst daily returns in the past 90 days and the best / worst monthly returns in the past 60 months.
- Volatility - The standard deviation of the stock price over the last 90 days and last 60 months, along with the average and largest intra-day stock swing.
- Beta - Measures the tendency of a security's returns to respond to swings in the market, based on the beta of the company versus the relevant index.
- Correlation - Determines how closely the returns of the stock and the relevant index move together, measured over the last 90 days and last 60 months.

Risk Analysis

Price analysis for the company and the relevant index is provided over two time periods. Daily analysis is provided for the last 90 days, whereas monthly statistics are used for the last 60 months.

Price Momentum

The Price Momentum Rating is based on a combination of two technical performance factors: relative strength and seasonality. The factors are equally weighted. Equal deciles are then used to rank each stock across the market on a scale of 1 to 10, with 10 being most favorable. A stock needs to have data for the relative strength factor in order to receive a score.

- Relative Strength - The relative strength of the company for the last 10 days, 50 days, and 200 days on a scale of 1 to 100.
- Seasonality - The average monthly return (price performance) for the current month and next 2 months for the company and industry, over the past 10 years. A lower industry rank indicates a higher return.

Price Performance

Daily close prices are used to calculate the price performance of the stock. The performance of the relevant index is also displayed as a means of comparison.

DISCLAIMER

© 2024 LSEG. All rights reserved. Republication or redistribution of LSEG content, including by framing or similar means, is prohibited without the prior written consent of LSEG. All information in this report is assumed to be accurate to the best of our ability. LSEG is not liable for any errors or delays in LSEG content, or for any actions taken in reliance on such content.

Any forward-looking statements included in the LSEG content are based on certain assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from current expectations. There is no assurance that any forward-looking statements will materialize.

The content in this LSEG report does not constitute investment advice or a recommendation to buy or sell securities of any kind. Past performance is not a guarantee of future results. Investors should consider this report as only a single factor when making an investment decision.